Last Updated: 19 Sep 2024
Executive Summary
LeMaitre Vascular Inc. (LMAT) is a medical device company that designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company has a strong financial performance with a market capitalization of $1.99 billion, EBITDA of $55.24 million, and EPS of $1.67. The stock is currently trading at $88.85, which is below the analyst target price of $95.75. The company has a positive outlook with expected growth in the coming years.
Company Overview
LeMaitre Vascular Inc. is headquartered in Burlington, Massachusetts. The company was founded in 1998 and has since become a leading provider of medical devices and implants for the treatment of peripheral vascular diseases. The company's products are used in a variety of procedures, including angioplasty, stenting, and atherectomy. LeMaitre Vascular Inc. has a global presence with operations in over 50 countries.
Fundamental Analysis
LeMaitre Vascular Inc. has a strong financial performance. The company's revenue has grown steadily in recent years, from $172.4 million in 2020 to $205.6 million in 2023. The company's net income has also grown steadily, from $20.1 million in 2020 to $37.4 million in 2023. The company's gross profit margin is 51.1%, and its operating margin is 25.8%. LeMaitre Vascular Inc. has a strong balance sheet with $104.9 million in cash and equivalents and $14.2 million in debt. The company's return on assets is 8.3%, and its return on equity is 12.5%.
Technical Analysis
The technical analysis of LeMaitre Vascular Inc. stock shows that the stock is currently in a bullish trend. The stock has been trading above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is 62.5, which indicates that the stock is overbought. The stock's stochastic oscillator is 80.0, which indicates that the stock is overbought.
Short Term Outlook
The short-term outlook for LeMaitre Vascular Inc. stock is positive. The stock is currently trading above its 50-day and 200-day moving averages. The stock's RSI and stochastic oscillator are both overbought, which indicates that the stock may be due for a pullback. However, the stock's overall trend is bullish, and it is likely to continue to rise in the short term.
Long Term Outlook
The long-term outlook for LeMaitre Vascular Inc. stock is also positive. The company has a strong financial performance and a growing product portfolio. The company is also expected to benefit from the increasing demand for medical devices and implants for the treatment of peripheral vascular diseases. The stock's analyst target price of $95.75 is a 7.8% upside from the current price.
Analyst Recommendations
The majority of analysts have a buy rating on LeMaitre Vascular Inc. stock. The average analyst target price is $95.75, which is a 7.8% upside from the current price.
